Loading…

Growth kinetics and immune response of chimeric foot-and-mouth disease virus serotype ‘O’ produced through replication competent mini genome of serotype Asia 1, 63/72, in BHK cell lines

► Here we report the production of chimeric FMDV ‘O’ using Asia 1 replicon. ► The chimeric virus replicated efficiently in BHK 21 cells to produce high titred virus ► The chimeric virus vaccine was found to be potent in vaccinated bovine calves. ► The backbone may be used for developing vaccines wit...

Full description

Saved in:
Bibliographic Details
Published in:Virus research 2013-05, Vol.173 (2), p.299-305
Main Authors: Joshi, Rahul, Chandrasekar, S., Paul, Soumya, Chokkalingam, Ashok Kumar, Saravanan, T., Ahmad, Kakoli, Dechamma, H.J., Reddy, G.R., Gopinath, S.M., Das, D.N., Shaila, M.S., Bharath, G.N., Suryanarayana, V.V.S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:► Here we report the production of chimeric FMDV ‘O’ using Asia 1 replicon. ► The chimeric virus replicated efficiently in BHK 21 cells to produce high titred virus ► The chimeric virus vaccine was found to be potent in vaccinated bovine calves. ► The backbone may be used for developing vaccines with other strains of interest. Regular vaccinations with potent vaccine, in endemic countries and vaccination to live in non-endemic countries are the methods available to control foot-and-mouth disease. Selection of candidate vaccine strain is not only cumbersome but the candidate should grow well for high potency vaccine preparation. Alternative strategy is to generate an infectious cDNA of a cell culture-adapted virus and use the replicon for development of tailor-made vaccines. We produced a chimeric ‘O’ virus in the backbone of Asia 1 and studied its characteristics. The chimeric virus showed high infectivity titre (>1010) in BHK 21 cell lines, revealed small plaque morphology and there was no cross reactivity with antiserum against Asia 1. The virus multiplies rapidly and reaches peak at 12h post infection. The vaccine prepared with this virus elicited high antibody titres.
ISSN:0168-1702
1872-7492
DOI:10.1016/j.virusres.2013.01.018